Desensitization of beta-adrenergic receptors by pheochromocytoma

Endocrinology
|April 1, 1984
PubMed

Insights

Pheochromocytoma in rats causes beta-adrenergic receptor desensitization, leading to reduced receptor numbers and function. This model helps study in vivo beta-adrenergic receptor desensitization mechanisms.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Cardiovascular Research

Background:

  • Prolonged beta-adrenergic receptor agonist stimulation can cause cellular desensitization.
  • Desensitization may involve receptor number reduction or altered receptor-effector coupling.

Purpose of the Study:

  • To investigate beta-adrenergic receptor desensitization in a rat model with pheochromocytoma.
  • To analyze the impact of high norepinephrine levels on beta-adrenergic receptors in vivo.

Main Methods:

  • Utilized pheochromocytoma-bearing rats with elevated norepinephrine levels.
  • Quantified beta-adrenergic receptors using [125I]iodocyanopindolol binding assays.
  • Assessed isoproterenol-stimulated cAMP accumulation in isolated adipocytes.

Main Results:

  • Observed significant down-regulation of beta 1-adrenergic receptors in heart and adipocytes.
  • Found diminished cAMP accumulation in adipocytes from pheochromocytomic rats.
  • Detected no change in beta 2-receptors in lung and mesenteric arteries.
  • Evidence of beta-adrenergic receptor uncoupling in heart membranes.

Conclusions:

  • Pheochromocytoma in rats serves as a valuable model for studying in vivo beta-adrenergic receptor desensitization.
  • Elevated norepinephrine levels contribute to beta 1-receptor down-regulation and uncoupling.
  • Desensitization involves both receptor number changes and functional alterations.

Related Concept Videos

Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...